125I seed irradiation induces apoptosis and inhibits angiogenesis by decreasing HIF-1α and VEGF expression in lung carcinoma xenografts

Xiang,Gui-Ling; Zhu,Xin-Hong; Lin,Cun-Zhi; Wang,Li-Jun; Sun,Yong; Cao,Yi-Wei; Wang,Fang-Fang

doi:10.3892/or.2017.5521

125I seed irradiation induces apoptosis and inhibits angiogenesis by decreasing HIF-1α and VEGF expression in lung carcinoma xenografts

Authors:
- Gui-Ling Xiang
- Xin-Hong Zhu
- Cun-Zhi Lin
- Li-Jun Wang
- Yong Sun
- Yi-Wei Cao
- Fang-Fang Wang
View Affiliations

Affiliations: Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of International Clinic, Qingdao Municipal Hospital, Qingdao, Shandong 266071, P.R. China
Published online on: March 23, 2017 https://doi.org/10.3892/or.2017.5521
Pages: 3075-3083

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The purpose of this study was to examine the effects of irradiation by 125I seeds in human lung cancer xenograft model and to determine the underlying mechanisms involved, with a focus on angiogenesis. A group of 40 mice bearing A549 lung adenocarcinoma xenografts was randomly separated into 4 groups: control group (n=10), sham seed (0 mCi) implant group (n=10), 125I seed (0.6 mCi) implant group (n=10) and 125I seed (0.8 mCi) implant group (n=10), respectively. The body weight and tumor volume, were recorded every four days until the end of the study. At 30 days after irradiation, the microvessel density, proliferative index and apoptotic index were evaluated by quantitative morphometric analysis of the expression of CD34, proliferating cell nuclear antigen (Ki-67) and in situ terminal transferase-mediated fluorescein deoxy- UTP nick-end labeling (TUNEL), respectively. The changes in the expression of hypoxia inducible factor-1α (HIF-1α) and vascular endothelial growth factor (VEGF) were detected by real-time PCR and western blot analysis. Consequently, 125I seed irradiation suppressed the growth of lung cancer xenografts in nude mice, while inhibiting cell proliferation and angiogenesis and inducing apoptosis as demonstrated by Ki67, CD34 and TUNEL staining. HIF-1α and VEGF mRNA and protein expression levels were substantially downregulated following 125I seed irradiation. Collectively, our data suggest that irradiation by 125I seeds is a promising new option for lung cancer treatment.

View Figures

View References

1	McGuire S: World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015. Adv Nutr. 7:418–419. 2016. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Zeng H, Zhang S and He J: Annual report on status of cancer in China, 2011. Chin J Cancer Res. 27:2–12. 2015. View Article : Google Scholar : PubMed/NCBI
3	Toyokawa G, Takenoyama M and Ichinose Y: Multimodality treatment with surgery for locally advanced non-small-cell lung cancer with n2 disease: A review article. Clin Lung Cancer. 16:6–14. 2015. View Article : Google Scholar : PubMed/NCBI
4	Cardenal F, Nadal E, Jové M and Faivre-Finn C: Concurrent systemic therapy with radiotherapy for the treatment of poor-risk patients with unresectable stage III non-small-cell lung cancer: A review of the literature. Ann Oncol. 26:278–288. 2015. View Article : Google Scholar : PubMed/NCBI
5	Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT, et al: American Society of Clinical Oncology: American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: Update 2003. J Clin Oncol. 22:330–353. 2004. View Article : Google Scholar : PubMed/NCBI
6	Dillman RO, Hemdon J, Seagren SL, Eaton WL Jr and Green MR: Improved survival in stage III non-small-cell lung cancer seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst. 88:1210–1215. 1996. View Article : Google Scholar : PubMed/NCBI
7	Wagner TD and Yang GY: The role of chemotherapy and radiation in the treatment of locally advanced non-small cell lung cancer (NSCLC). Curr Drug Targets. 11:67–73. 2010. View Article : Google Scholar : PubMed/NCBI
8	Liew MS, Sia J, Starmans MH, Tafreshi A, Harris S, Feigen M, White S, Zimet A, Lambin P, Boutros PC, et al: Comparison of toxicity and outcomes of concurrent radiotherapy with carboplatin/paclitaxel or cisplatin/etoposide in stage III non-small cell lung cancer. Cancer Med. 2:916–924. 2013. View Article : Google Scholar : PubMed/NCBI
9	Cannon DM, Mehta MP, Adkison JB, Khuntia D, Traynor AM, Tomé WA, Chappell RJ, Tolakanahalli R, Mohindra P, Bentzen SM, et al: Dose-limiting toxicity after hypofractionated dose-escalated radiotherapy in non-small-cell lung cancer. J Clin Oncol. 31:4343–4348. 2013. View Article : Google Scholar : PubMed/NCBI
10	Park DS, Gong IH, Choi DK, Hwang JH, Shin HS and Oh JJ: Radical prostatectomy versus high dose permanent prostate brachytherapy using iodine-125 seeds for patients with high risk prostate cancer: A matched cohort analysis. World J Urol. 31:1511–1517. 2013. View Article : Google Scholar : PubMed/NCBI
11	Wang ZM, Lu J, Liu T, Chen KM, Huang G and Liu FJ: CT-guided interstitial brachytherapy of inoperable non-small cell lung cancer. Lung Cancer. 74:253–257. 2011. View Article : Google Scholar : PubMed/NCBI
12	Joyce F, Burcharth F, Holm HH and Strøyer I: Ultrasonically guided percutaneous implantation of iodine-125 seeds in pancreatic caicinoma. Int J Radiat Oncol Biol Phys. 19:1049–1052. 1990. View Article : Google Scholar : PubMed/NCBI
13	Wang JJ, Yuan HS, Li JN, Jiang WJ, Jiang YL and Tian SQ: Interstitial permanent implantation of 125I seeds as salvage therapy for re-recurrent rectal carcinoma. Int J Colorectal Dis. 24:391–399. 2009. View Article : Google Scholar : PubMed/NCBI
14	Jiang Y-L, Meng N, Wang J-J, Ran WQ, Yuan HS, Qu A and Yang RJ: Percutaneous computed tomography/ultrasonography-guided permanent iodine-125 implantation as salvage therapy for recurrent squamous cell cancers of head and neck. Cancer Biol Ther. 9:959–966. 2010. View Article : Google Scholar : PubMed/NCBI
15	Zhang FJ, Li CX, Zhang L, Wu PH, Jiao DC and Duan GF: Short- to mid-term evaluation of CT-guided 125I brachytherapy on intra-hepatic recurrent tumors and/or extra-hepatic metastases after liver transplantation for hepatocellular carcinoma. Cancer Biol Ther. 8:585–590. 2009. View Article : Google Scholar : PubMed/NCBI
16	Heelan RT, Hilaris BS, Anderson LL, Nori D, Martini N, Watson RC, Caravelli JF and Linares LA: Lung tumors: Percutaneous implantation of I-125 sources with CT treatment planning. Radiology. 164:735–740. 1987. View Article : Google Scholar : PubMed/NCBI
17	Li W, Guan J, Yang L, Zheng X, Yu Y and Jiang J: Iodine-125 brachytherapy improved overall survival of patients with inoperable stage III/IV non-small cell lung cancer versus the conventional radiotherapy. Med Oncol. 32:3952015. View Article : Google Scholar : PubMed/NCBI
18	Qu A, Wang H, Li J, Wang J, Liu J, Hou Y, Huang L and Zhao Y: Biological effects of (125)i seeds radiation on A549 lung cancer cells: G2/M arrest and enhanced cell death. Cancer Invest. 32:209–217. 2014. View Article : Google Scholar : PubMed/NCBI
19	Takabayashi K, Kashiwagi K, Kawata T, Sato T, Matsuoka K, Hisamatsu T, Takaishi H, Hibi T, Ogata H, Yahagi N, et al: Continuous low-dose irradiation by I-125 seeds induces apoptosis of gastric cancer cells regardless of histological origin. Cancer Biol Ther. 15:81–88. 2014. View Article : Google Scholar : PubMed/NCBI
20	Carmeliet P: Manipulating angiogenesis in medicine. J Intern Med. 255:538–561. 2004. View Article : Google Scholar : PubMed/NCBI
21	Acker T and Plate KH: A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology. J Mol Med (Berl). 80:562–575. 2002. View Article : Google Scholar : PubMed/NCBI
22	Folkman J: Tumor angiogenesis: Therapeutic implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
23	Lee JW, Shahzad MM, Lin YG, Armaiz-Pena G, Mangala LS, Han HD, Kim HS, Nam EJ, Jennings NB, Halder J, et al: Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res. 15:2695–2702. 2009. View Article : Google Scholar : PubMed/NCBI
24	Hong S-S, Lee H and Kim K-W: HIF-1α: A valid therapeutic target for tumor therapy. Cancer Res Treat. 36:343–353. 2004. View Article : Google Scholar : PubMed/NCBI
25	Thangarajah H, Yao D, Chang EI, Shi Y, Jazayeri L, Vial IN, Galiano RD, Du XL, Grogan R, Galvez MG, et al: The molecular basis for impaired hypoxia-induced VEGF expression in diabetic tissues. Proc Natl Acad Sci USA. 106:13505–13510. 2009. View Article : Google Scholar : PubMed/NCBI
26	Peretz T, Nori D, Hilaris B, Manolatos S, Linares L, Harrison L, Anderson LL, Fuks Z and Brennan MF: Treatment of primary unresectable carcinoma of the pancreas with I-125 implantation. Int J Radiat Oncol Biol Phys. 17:931–935. 1989. View Article : Google Scholar : PubMed/NCBI
27	Mazeron JJ, Noël G, Simon JM, Racadot S and Jauffret E: Brachytherapy in head and neck cancers. Cancer Radiother. 7:62–72. 2003.(In French). View Article : Google Scholar : PubMed/NCBI
28	Yu L, Chen H and Cheng W: Influence of ~(125)I continuous low dose-rate irradiation to apoptosis and DNA-PK expression of human lung carcinoma cell lines. Chinese J Clin Med. 6:2007.
29	Lin X, Li HR, Lin XF, Yu ME, Tu XW, Hua ZD, Lin M, Xu NL, Han LL and Chen YS: Silencing of Livin inhibits tumorigenesis and metastasis via VEGF and MMPs pathway in lung cancer. Int J Oncol. 47:657–667. 2015.PubMed/NCBI
30	Semenza GL: Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
31	Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P and Grossi F: Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol. 68:183–196. 2008. View Article : Google Scholar : PubMed/NCBI
32	Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U and Stein H: Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 133:1710–1715. 1984.PubMed/NCBI
33	Semenza GL: Involvement of hypoxia-inducible factor 1 in human cancer. Intern Med. 41:79–83. 2002. View Article : Google Scholar : PubMed/NCBI
34	Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 16:4604–4613. 1996. View Article : Google Scholar : PubMed/NCBI
35	Semenza GL: Hypoxia-inducible factor 1: Master regulator of O₂ homeostasis. Curr Opin Genet Dev. 8:588–594. 1998. View Article : Google Scholar : PubMed/NCBI
36	Wang GL, Jiang BH, Rue EA and Semenza GL: Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O₂ tension. Proc Natl Acad Sci USA. 92:5510–5514. 1995. View Article : Google Scholar : PubMed/NCBI
37	Fukuda R, Hirota K, Fan F, Jung YD, Ellis LM and Semenza GL: Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J Biol Chem. 277:38205–38211. 2002. View Article : Google Scholar : PubMed/NCBI
38	Kerbel RS: New targets, drugs, and approaches for the treatment of cancer: An overview. Cancer Metastasis Rev. 17:145–147. 1998. View Article : Google Scholar : PubMed/NCBI
39	Mouriaux F, Sanschagrin F, Diorio C, Landreville S, Comoz F, Petit E, Bernaudin M, Rousseau AP, Bergeron D and Morcos M: Increased HIF-1α expression correlates with cell proliferation and vascular markers CD31 and VEGF-A in uveal melanoma. Invest Ophthalmol Vis Sci. 55:1277–1283. 2014. View Article : Google Scholar : PubMed/NCBI
40	Harada H: How can we overcome tumor hypoxia in radiation therapy? J Radiat Res (Tokyo). 52:545–556. 2011. View Article : Google Scholar
41	Iwasaki A, Kuwahara M, Yoshinaga Y and Shirakusa T: Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg. 25:443–448. 2004. View Article : Google Scholar : PubMed/NCBI
42	Kishiro I, Kato S, Fuse D, Yoshida T, Machida S and Kaneko N: Clinical significance of vascular endothelial growth factor in patients with primary lung cancer. Respirology. 7:93–98. 2002. View Article : Google Scholar : PubMed/NCBI